XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05540340` - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant	Phase 1
Completed	`NCT03415399` - Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma	Phase 1
Withdrawn	`NCT03605589` - Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma	Phase 1
Recruiting	`NCT04807881` - Phase Ib Clinical Study of Keynatinib	Phase 1
Completed	`NCT05510596` - Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome	N/A
Not yet recruiting	`NCT06350994` - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Terminated	`NCT02670317` - Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.	Phase 2
Completed	`NCT00998946` - Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma	Phase 2
Terminated	`NCT00768339` - A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas	Phase 1/Phase 2
Withdrawn	`NCT00538096` - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma	Phase 1
Terminated	`NCT00521638` - Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00379574` - Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL	Phase 1/Phase 2
Completed	`NCT00156013` - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)	Phase 1/Phase 2
Completed	`NCT00147121` - Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)	Phase 2/Phase 3
Recruiting	`NCT04594798` - A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL	Phase 2
Recruiting	`NCT04161248` - Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma	Early Phase 1
Withdrawn	`NCT04052061` - QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma	Phase 1
Recruiting	`NCT04884035` - Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma	Phase 1
Not yet recruiting	`NCT05834426` - Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
Recruiting	`NCT05376709` - A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population	N/A

NCT number	NCT03598179
Study type	Interventional
Source	The First Affiliated Hospital with Nanjing Medical University
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 1, 2018
Completion date	July 1, 2020

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms